Compare Abeona Therapeutics Inc (ABEO) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while VanEck Rare Earth/Strategic Metals trades at $78.9. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| ABEO | REMX | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $109.53 |
52-Week Low | $4.17 | $41.94 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
REMX trades at $85.34, down 1.59% today, with a bearish technical signal driven by moving averages. The ETF is positioned in the rare earth and strategic metals sector, benefiting from geopolitical tensions and supply chain shifts. Recent news highlights strong institutional interest in materials and commodities, with REMX recognized for AI infrastructure and defense exposure. Key support is at $84, with resistance at $86.
Outlook is mixed; rare earth demand is rising due to AI and energy transitions, but high concentration and volatility pose risks. Investment opportunity lies in commodity cycle exposure, yet investors face geopolitical and inflation uncertainties. Wall Street sentiment is cautious despite thematic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
